繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
牛牛AI助理已提取核心訊息
On November 14, 2024, BeiGene USA, Inc. and BeiGene Switzerland GmbH reached a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd., resolving patent litigation related to BRUKINSA (zanubrutinib). The litigation was initiated in response to MSN's ANDA filing seeking approval for a generic version of BRUKINSA. BeiGene granted MSN the right to sell a generic version in the US no earlier than June 15, 2037, subject to potential adjustments.The composition of matter patent for BRUKINSA, expiring in April 2034, was not challenged in the litigation. This settlement, along with the previous dismissal of litigation against Sandoz Inc., resolves all patent litigation brought by BeiGene against companies seeking to market generic versions of BRUKINSA. As required by law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice.
On November 14, 2024, BeiGene USA, Inc. and BeiGene Switzerland GmbH reached a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd., resolving patent litigation related to BRUKINSA (zanubrutinib). The litigation was initiated in response to MSN's ANDA filing seeking approval for a generic version of BRUKINSA. BeiGene granted MSN the right to sell a generic version in the US no earlier than June 15, 2037, subject to potential adjustments.The composition of matter patent for BRUKINSA, expiring in April 2034, was not challenged in the litigation. This settlement, along with the previous dismissal of litigation against Sandoz Inc., resolves all patent litigation brought by BeiGene against companies seeking to market generic versions of BRUKINSA. As required by law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice.
在2024年11月14日,百濟神州美國公司和百濟神州瑞士公司與MSN製藥公司和MSN實驗室私人有限公司達成了一項和解協議,解決與BRUKINSA(扎努布魯侖)相關的專利訴訟。該訴訟是對MSN提出的ANDA申請尋求批准百濟神州的仿製版的回應。百濟神州授予MSN在美國銷售該仿製版的權利,最早不早於2037年6月15日,具體日期可能會調整。BRUKINSA的物質組成專利將在2034年4月到期,訴訟中未對此提出挑戰。此次和解以及之前對Sandoz Inc.的訴訟被駁回,解決了百濟神州針對尋求銷售BRUKINSA仿製版的公司的所有專利訴訟。根據法律要求,和解協議將提交給美國聯邦貿易委員會和美國司法部。
在2024年11月14日,百濟神州美國公司和百濟神州瑞士公司與MSN製藥公司和MSN實驗室私人有限公司達成了一項和解協議,解決與BRUKINSA(扎努布魯侖)相關的專利訴訟。該訴訟是對MSN提出的ANDA申請尋求批准百濟神州的仿製版的回應。百濟神州授予MSN在美國銷售該仿製版的權利,最早不早於2037年6月15日,具體日期可能會調整。BRUKINSA的物質組成專利將在2034年4月到期,訴訟中未對此提出挑戰。此次和解以及之前對Sandoz Inc.的訴訟被駁回,解決了百濟神州針對尋求銷售BRUKINSA仿製版的公司的所有專利訴訟。根據法律要求,和解協議將提交給美國聯邦貿易委員會和美國司法部。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了